Novel Mechanisms of Action in Schizophrenia Treatment

In "Novel Mechanisms of Action in Schizophrenia Treatment," our panel explores the science, clinical profile, and therapeutic potential of xanomeline/trospium chloride, the first FDA-approved antipsychotic to work through muscarinic cholinergic modulation rather than postsynaptic dopamine blockade.

Dr. Christoph Correll opens by reframing the role of the cholinergic system in schizophrenia, explaining that acetylcholine — acting through M1 and M4 muscarinic receptors — modulates multiple neurotransmitter systems including dopamine, GABA, and glutamate. Unlike conventional antipsychotics that broadly block postsynaptic dopamine receptors, xanomeline acts presynaptically via M4 agonism to reduce excess dopamine release in areas associated with psychosis, while M1 postsynaptic agonism may enhance dopaminergic and glutamatergic activity in the prefrontal cortex — an area implicated in cognitive and negative symptoms. This dual directionality and regional selectivity, Dr. Correll argues, represents a true revolution in schizophrenia pharmacology.

Because xanomeline's pro-cholinergic activity produces peripheral gastrointestinal side effects, it is co-formulated with trospium chloride, a peripherally restricted anticholinergic that buffers these effects without crossing the blood-brain barrier. Critically, by avoiding postsynaptic dopamine blockade entirely, xanomeline/trospium chloride sidesteps five major side effect categories associated with current antipsychotics: extrapyramidal symptoms, tardive dyskinesia, prolactin elevation, metabolic abnormalities and weight gain, and sedation or insomnia. However, residual gastrointestinal side effects remain, with nausea occurring in approximately 17% of patients, vomiting in 11%, and constipation and dyspepsia in roughly 12–15% — effects that appear somewhat time-limited.

Dr. Correll also reviews the ARISE augmentation study, noting mixed results in the overall population but promising signals in non-risperidone subgroups, and cautions that the short duration of existing trials may have limited the opportunity to observe the drug's full efficacy potential. He closes with cautious optimism that xanomeline/trospium chloride — either as augmentation or monotherapy — may ultimately benefit patients not only through its improved side effect profile but through genuinely differentiated efficacy, particularly for those with treatment-resistant or partially responsive schizophrenia.

Our next episode, "Integrating Novel Mechanisms into Schizophrenia Treatment Practice," examines how clinicians are incorporating novel mechanisms of action into real-world practice, illustrating through a compelling case study how the agent can offer a viable pathway for patients who have failed prior therapies, including clozapine, while reducing the monitoring burden associated with existing treatments.